SeekIn Presents New Data Supporting its Pan-cancer Early Detection Test at the Early Detection of Cancer Conference 2022

The large case-control study demonstrates that SeekInCare® has 68.0% sensitivity at 98.0% specificity in 27 different cancer types as a whole.

In both retrospective and prospective studies, the solid performance of SeekInCare® puts it into best-in-class category of multi-cancer early detection (MCED) test.

https://www.biospace.com/article/releases/seekin-presents-new-data-supporting-its-pan-cancer-early-detection-test-at-the-early-detection-of-cancer-conference-2022/